Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

*Nature Medicine* published an author correction on May 5, 2026, regarding a phase 3 clinical trial that evaluated the efficacy of benralizumab compared to a placebo for the treatment of hypereosinophilic syndrome.

The trial, titled Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial, focused on the impact of the drug on patients suffering from this rare inflammatory condition.

Understanding Hypereosinophilic Syndrome

Hypereosinophilic syndrome, or HES, is a group of disorders characterized by a persistent and abnormal increase in eosinophils, a type of white blood cell. While eosinophils are essential for fighting parasites and responding to allergens, an excessive accumulation of these cells can lead to systemic inflammation.

When eosinophil levels remain pathologically high, they can release cytotoxic proteins and other inflammatory mediators that cause damage to various organs. The most commonly affected areas include the heart, lungs, skin and gastrointestinal tract.

Patients with HES may experience a wide array of symptoms depending on which organs are compromised. These can include shortness of breath, heart failure, skin rashes, and neurological deficits.

Mechanism of Benralizumab

Benralizumab is a monoclonal antibody designed to target the interleukin-5 receptor alpha (IL-5Rα) on the surface of eosinophils. Interleukin-5 is a key cytokine responsible for the growth, activation, and survival of eosinophils.

By binding directly to the receptor, benralizumab not only blocks the signaling of IL-5 but also induces the rapid depletion of eosinophils through a process called antibody-dependent cell-mediated cytotoxicity (ADCC). This process utilizes natural killer cells to eliminate the targeted eosinophils from the bloodstream and tissues.

This mechanism differs from other IL-5 inhibitors that target the cytokine itself, as benralizumab targets the receptor, potentially leading to a more complete and rapid reduction in eosinophil counts.

The Role of Phase 3 Trials and Corrections

The study in question was a phase 3 trial, which represents the final stage of clinical testing before a treatment is submitted for regulatory approval for a specific indication. Phase 3 trials are randomized and placebo-controlled, designed to confirm the efficacy and monitor the safety of a drug in a larger patient population.

In the context of HES, these trials seek to determine if the reduction of eosinophil counts translates into a meaningful improvement in clinical symptoms and a reduction in organ damage.

The issuance of an author correction by *Nature Medicine* is a standard part of the scientific process. Corrections are utilized to rectify errors in the original publication—such as typographical mistakes, inaccuracies in data tables, or omissions in author lists—to ensure the permanent scientific record remains accurate.

Maintaining the integrity of trial data is critical for clinicians who rely on peer-reviewed literature to make treatment decisions for patients with rare diseases like hypereosinophilic syndrome.